XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
M
M

Morphosys


Actualités

Morphosys Announces Voluntary Delisting From The Nasdaq Global Market

BRIEF-Morphosys Announces Voluntary Delisting From The Nasdaq Global Market July 12 (Reuters) - MorphoSys AG MORG.DE : EQS-NEWS: MORPHOSYS ANNOUNCES VOLUNTARY DELISTING FROM THE NASDAQ GLOBAL MARKET MORPHOSYS AG - EXPECTS THAT LAST TRADING DAY ON NASDAQ WILL BE ON OR ABOUT AUGUST 2, 2024 Source text for Eikon: ID:nEQ1B29X1a Further company coverage
M

Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00

BRIEF-Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00 July 12 (Reuters) - MORPHOSYS AG MORG.DE : MERGER SQUEEZE-OUT CASH COMPENSATION DETERMINED AT EUR 68.00 ANNOUNCES THAT NOVARTIS BIDCO GERMANY AG SUBMITTED A SPECIFIED REQUEST (KONKRETISIERTES VERLANGEN) TO MORPHOSYS AG MANAGEMENT BOARD COURT-APPOINTED EXPERT AUDITOR H
M

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N

Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO

BRIEF-Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO June 7 (Reuters) - MORPHOSYS AG MORG.DE : EQS-ADHOC: AD HOC: ARKADIUS PICHOTA AND LUKAS GILGEN APPOINTED TO MANAGEMENT BOARD OF MORPHOSYS AG REPLACING THE CURRENT CEO AND CFO Source text for Eikon: ID:nEQQh9gja Further company coverage: MORG.DE (Gdansk Newsroom)
M

Novartis Meets All Tender Offer Conditions To Acquire Morphosys

BRIEF-Novartis Meets All Tender Offer Conditions To Acquire Morphosys May 16 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS MEETS ALL TENDER OFFER CONDITIONS TO ACQUIRE MORPHOSYS AG FOR EUR 68 PER SHARE IN CASH SETTLEMENT OF SHARES TENDERED DURING INITIAL ACCEPTANCE PERIOD IS EXPECTED TO OCCUR ON 23 MAY 2024 Source text for Eikon: ID:nGNEcc97X3 Further
M
N

Novartis to buy radiology drug specialist Mariana for $1 billion

UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion Adds details on technology in paragraphs 5 and 6 By Andrey Sychev and Ludwig Burger May 2 (Reuters) - Novartis NOVN.S agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday.
M
N

Incyte misses quarterly profit on weak sales of lead drug

Incyte misses quarterly profit on weak sales of lead drug April 30 (Reuters) - Incyte Corp INCY.O on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade.
I
M
N

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Impossible foods, WeWork and Anglo American April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 16:15 GMT on Monday: ** Impossible Foods, which makes meat alternatives from soy, is targeting a "liquidity event" that could include a public offering in the next two to three years, CEO Peter McGuinness told Reuters.
A
M
N
T
A

Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked

BRIEF-Morphosys AG Says 2024 Financial Guidance Published On January 30, 2024, Cannot Be Maintained And Therefore Was Revoked April 29 (Reuters) - MorphoSys AG MORG.DE : MORPHOSYS' 2024 FINANCIAL GUIDANCE PUBLISHED ON JANUARY 30, 2024, CANNOT BE MAINTAINED AND THEREFORE WAS REVOKED WILL NO LONGER MAKE A FORECAST FOR GROSS MARGIN OR REVENUES FROM MONJUVI PRODUCT SALES COST OF SALES IN Q1 OF 2024 AMOUNTED TO EUR 2.8 MILLION (3M 2023: EUR 1.0 MILLION) FOR 2024, MORPHOSYS EXPECTS RESEARCH AND DEVELO
M

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Manipal Hospitals, WEC Energy Group, Thyssenkrupp, UMB Financial Corp, Investcorp, Deciphera; updates BHP Group, Morphosys April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** India's Manipal Hospitals said it will acquire an 87% stake in Medica Synergie as it aims to expand its footprint in eastern India.
A
M
N
T
A

Morphosys says takeover by Novartis on course after report of drug safety concern

UPDATE 1-Morphosys says takeover by Novartis on course after report of drug safety concern Writes through with detail, background, no Novartis comment; adds shares in final paragraph BERLIN, April 29 (Reuters) - Morphosys MORG.DE said its takeover by Novartis NOVN.S is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday.
M
N

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** Morphosys MORG.DE said its takeover by Novartis NOVN.S was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price.
A
M
N
A

Morphosys says Novartis takeover progressing as planned for H1 2024

Morphosys says Novartis takeover progressing as planned for H1 2024 BERLIN, April 29 (Reuters) - Morphosys MORG.DE said its takeover by Novartis NOVN.S was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price on Monday.
M
N

MorphoSys AG <MOR.OQ> expected to post a loss of 32 cents a share - Earnings Preview

MorphoSys AG expected to post a loss of 32 cents a share - Earnings Preview MorphoSys AG MOR.OQ , MOR.O is expected to show a fall in quarterly revenue when it reports results on April 29 for the period ending March 31 2024 The Planegg Bayern-based company is expected to report a 11.0% decrease in revenue to €55.448 million from €62.32 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
M

Morphosys To Present New Phase 3 Manifest-2 Data On Pelabresib In Myelofibrosis

BRIEF-Morphosys To Present New Phase 3 Manifest-2 Data On Pelabresib In Myelofibrosis April 24 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS TO PRESENT NEW PHASE 3 MANIFEST-2 DATA ON PELABRESIB IN MYELOFIBROSIS IN ORAL PRESENTATION AT 2024 ASCO ANNUAL MEETING Source text for Eikon: ID:nEQ81FfT1a Further company coverage: MORG.DE (Gdansk Newsroom)
M

Novartis raises guidance after beating Q1 expectations

UPDATE 4-Novartis raises guidance after beating Q1 expectations Adds analyst comment, shares in paragraphs 6-7 By Ludwig Burger FRANKFURT, April 23 (Reuters) - Swiss drugmaker Novartis NOVN.S raised its full-year guidance on wider use of psoriasis and arthritis drug Cosentyx on Tuesday and said it had tapped the former boss of Bristol Myers Squibb (BMS) to become its chairman next year.
M
N



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques